Barrington Research analyst Vincent Colicchio maintains TD Synnex (NYSE:SNX) with a Outperform and lowers the price target from $128 to $106.
FDA Asks For Additional Successful Trial To Approve Soligenix’s Rare Cancer Candidate
Soligenix Inc (NASDAQ:SNGX) convened a Type A Meeting with the FDA, discussing the contents of a refusal to file (RTF)…